title: Systemic aspergillosis in a patient with non-Hodgkin's lymphoma developing acute graft-versus-host disease after autologous peripheral blood stem cell transplantation.
abstract: Graft-versus-host disease (GVHD) is rare in the autologous setting. We describe a non-Hodgkin's lymphoma case developing acute GVHD after autologous peripheral blood stem cell transplantation following several lines of chemotherapy inclusive of fludarabine. At day +33, he complained of fever, diffused erythematous papulosis with ulceration of skin lesions. A punch biopsy indicated a grade III GVHD. A dose escalation of corticosteroids, cyclosporin-A and photoapheresis induced a transient response. He developed positivity to CMV and systemic aspergillosis. He died at day +185 in haematological complete remission, despite infection-oriented treatment. In spite of the use of prophylactic immunosuppressive drugs, between 50% and 70% of patients given HLA-identical marrow graft develop acute graft-versus-host disease (GVHD) that, in turn, significantly increases the risk of transplant-related mortality. Autologous BMT has been shown to be an effective procedure in several malignancies, persistently becoming a first-line choice in treating patients affected with lymphoproliferative disorders, specially non-Hodgkin's lymphoma (NHL). Although GVHD is a very rare event in the autologous setting (AuGVHD), a consistent number of reports dealing with GVHD-like phenomena has emerged, especially in breast cancer patients. More often, AuGVHD has been induced by the use of immunosuppressive agents, such as cyclosporin-A (CSA), in attempt to evoke a graft-versus-tumor (GVT) effect. However, AuGVHD is mild and self-limited phenomenon. We report the case of a NHL patient who developed unresponsive GVHD after autologous peripheral blood stem cell transplantation (PBSCT). Because of the immunosuppressive therapies, he developed systemic aspergillosis. He died in haematological complete remission despite infection-oriented treatment.
authors.affiliation: Centro Trapianti di Midollo Osseo e Terapia Sovramassimali Emato-Oncologiche Alberto Neri, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy. gspmessina@virgilio.it
authors.forename: G
authors.initials: G
authors.lastname: Messina
authors.forename: E
authors.initials: E
authors.lastname: Quartarone
authors.forename: G
authors.initials: G
authors.lastname: Console
authors.forename: M
authors.initials: M
authors.lastname: Cuzzola
authors.forename: O
authors.initials: O
authors.lastname: Iacopino
authors.forename: M
authors.initials: M
authors.lastname: Martino
authors.forename: G
authors.initials: G
authors.lastname: Irrera
authors.forename: F
authors.initials: F
authors.lastname: Morabito
authors.forename: P
authors.initials: P
authors.lastname: Iacopino
mesh_terms: D000208:Acute Disease; D001228:Aspergillosis / Q000188:drug therapy / Q000209:etiology*; D017809:Fatal Outcome; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000382:microbiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000382:microbiology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000188:drug therapy / Q000209:etiology; D014182:Transplantation, Autologous / Q000009:adverse effects